Gilead Sciences Inc’s experimental cocktail to treat HIV received a green light from European regulators on Friday, boosting the chances of the drug being formally approved by the European Commission.
The European Medicines Agency issued a positive opinion on the treatment, Descovy, a combination of emtricitabine and tenofovir alafenamide. Both drugs stop HIV from multiplying.
Source: Reuters
Filed Under: Drug Discovery
